Surging Respiratory Disease Cases Fuel Growth In The Severe Acute Respiratory Syndrome Treatment Market: The Driving Engine Behind Severe Acute Respiratory-Syndrome Treatment Market Evolution in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts

Severe Acute Respiratory-Syndrome Treatment Market Size Growth Forecast: What to Expect by 2025?
There has been a swift expansion in the market size of severe acute respiratory syndrome treatments in the last few years. It is projected to escalate from a valuation of $3.45 billion in 2024 to $3.97 billion in 2025, registering a compound annual growth rate (CAGR) of 15.2%. Factors contributing to this substantial growth during the historic period include the global response to disease outbreaks, advancements in antiviral drug development, vaccine creation, and public health readiness preparations.

How Will the Severe Acute Respiratory-Syndrome Treatment Market Size Evolve and Grow by 2029?
It's anticipated that the market size for the treatment of severe acute respiratory syndrome will experience accelerated expansion in the forthcoming years. It is predicted to reach a worth of $7.15 billion in 2029, with a Compound Annual Growth Rate (CAGR) of 15.8%. This surge during the forecast period can be credited to extensive antivirals, developing therapeutics, advancements in vaccines, and readiness for pandemics. Key trends during this forecast period encompass RNA-targeted therapies, the utilization of AI in drug discovery, worldwide collaborations, and education in public health.

View the full report here:
https://www.thebusinessresearchcompany.com/report/severe-acute-respiratory-syndrome-treatment-global-market-report

What Drivers Are Propelling the Growth of Severe Acute Respiratory-Syndrome Treatment Market Forward?
The rising occurrence of conditions affecting the respiratory system appears to be fueling the growth of the market for severe acute respiratory syndrome treatment. Such diseases impact the system that allows for the process of breathing and gas exchange between the body and its external environment. Interventions for severe acute respiratory syndrome are utilized in such instances to provide symptom relief, prevent respiratory failure, minimize inflammation, and regulate oxygen levels. For example, as per the National Asthma Council, an Australian non-profit organization dedicated to enhancing asthma care and management, 467 asthma-related fatalities were reported in 2022 - an increase from the 355 deaths in 2021. This rising trend in respiratory ailments contributes to the expansion of the severe acute respiratory syndrome treatment market. The market for severe acute respiratory syndrome treatment is also likely to be propelled by increased funding for research and development. This term pertains to the resources - financial and human - that organizations, governments, or entities allocate to conduct inventive and systematic research to acquire new knowledge. Elevated funding for such activities can significantly enhance the treatments available for severe acute respiratory conditions such as SARS and COVID-19. It can lead to the creation of powerful drugs, vaccines, diagnostic tools, and therapeutic strategies, thereby enhancing patient outcomes and preparation for global health emergencies. In an illustration of this, the United States Department of Health and Human Services stated in August 2023 that over $1.4 billion had been awarded to Project NextGen through the Administration for Strategic Preparedness and Response (ASPR). This funding will support the creation of new-generation COVID-19 vaccines and therapies. Consequently, rising funding for research and development activities is leading to the growth of the severe acute respiratory syndrome treatment market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13027&type=smp

Which Emerging Trends Are Transforming the Severe Acute Respiratory-Syndrome Treatment Market in 2025?
Leading firms in the severe acute respiratory syndrome treatment market are leveraging novel methodologies like multiplexed real-time PCR to strengthen their market position. This technology in molecular biology allows for the expansion and identification of multiple DNA or RNA targets within one process. For instance, in July 2022, the Beijing-based molecular and cellular biology research and manufacturing company, TransGen Biotech Co. Ltd., unveiled the Trans-SARS-CoV-2, Influenza A and B and Respiratory Syncytial Virus Assay. This avant-garde assay, which functions on multiplexed real-time PCR, aids in the detection and distinction of severe acute respiratory syndrome COVID-19 2 (SARS CoV 2), Influenza A, Influenza B and respiratory syncytial virus (RSV) from a single sample. Furthermore, the assay is a useful instrument in diagnosing and treating SARS, influenza, and RSV, contributing to treatment guidance and disease spread prevention.

What Are the Key Segments in the Severe Acute Respiratory-Syndrome Treatment Market?
The severe acute respiratory-syndrome treatment market covered in this report is segmented -

1) By Drug Class: Antibiotics, Antiviral, Corticosteroids, Monoclonal Antibodies, Other Drug Classes
2) By Route Of Administration: Oral, Intravenous
3) By Indication: Severe Acute Respiratory Syndrome COVID-19 (SARS-CoV), Severe Acute Respiratory Syndrome COVID-19 2 (SARS-CoV-2)
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

Subsegments:
1) By Antibiotics: Broad-Spectrum Antibiotics, Narrow-Spectrum Antibiotics
2) By Antiviral: Nucleoside Analogs, Protease Inhibitors
3) By Corticosteroids: Systemic Corticosteroids, Inhaled Corticosteroids
4) By Monoclonal Antibodies: Neutralizing Antibodies, Non-Neutralizing Antibodies
5) By Other Drug Classes: Immunomodulators, Supportive Medications

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=13027&type=smp

Who Are the Key Players Shaping the Severe Acute Respiratory-Syndrome Treatment Market's Competitive Landscape?
Major companies operating in the severe acute respiratory-syndrome treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Merck And Co Inc., Novartis AG, Bristol Myers Squib company, GlaxoSmithKline PLC, AstraZeneca PLC, Sanofi SA, Eli Lilly And Company, Gilead Sciences Inc., Amgen Inc., Johnson And Johnson Private Limited, Moderna Inc., Regeneron Pharmaceuticals Inc., Hetero labs Ltd., Alexion Pharmaceuticals Inc., Cadila healthcare Ltd., Genentech Inc., Cipla Ltd., Biogen Inc., Vir Biotechnology Inc., Swedish Orphan Biovitrum AB, Dynavax Technologies Corporation, ViiV Healthcare Limited, Panacea Biotec Limited, CureVac N.V., CN Bio Innovations Ltd., Inovio Pharmaceuticals Inc., Chimerix Inc.

What Geographic Markets Are Powering Growth in the Severe Acute Respiratory-Syndrome Treatment Market?
North America was the largest region in the severe acute respiratory syndrome treatment market in 2024. Western Europe is expected to be the fastest-growing region in the forecast period. The regions covered in severe acute respiratory syndrome treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13027

"This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work."

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.